@phdthesis{Mueller2014,
  author    = {M{\"u}ller, Markus},
  title     = {Effekte kardioprotektiver Zyklopeptide auf Funktion und Morphometrie des Herzens im Rattenmodell der dilatativen Immunkardiomyopathie},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-101935},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2014},
  abstract  = {Kardiomyopathien sind Erkrankungen des Herzmuskels, die mit einer kardialen Funktionsst{\"o}rung einhergehen. Formen, die ohne erkennbare Ursache zu einer progredienten Dilatation und Reduktion der Kontraktilit{\"a}t des linken Ventrikels f{\"u}hren, werden als idiopathische dilatative Kardiomyopathie (DCM) bezeichnet. Sie ist der Hauptgrund f{\"u}r schwere Herzinsuffizienz und die damit assoziierten Einschr{\"a}nkungen der Lebensqualit{\"a}t bei jungen Erwachsenen. Neben der beeintr{\"a}chtigten kardialen Funktion weisen diese Patienten oftmals auch Ver{\"a}nderungen im Bereich der humoralen und zellul{\"a}ren Immunit{\"a}t auf. Ein Teil der Patienten entwickelt Autoantik{\"o}rper, die sich gegen den kardialen β1-adrenergen Rezeptor richten und ihn {\"a}hnlich wie der nat{\"u}rliche Ligand Adrenalin aktivieren. Hieraus resultiert eine chronische {\"U}berstimulation des Rezeptors, die {\"u}ber eine initiale Hypertrophie dann zu einer eingeschr{\"a}nkten Pumpfunktion f{\"u}hrt. Nachdem sich die Therapie der Antik{\"o}rper-vermittelten Immunkardiomyopathie bisher auf die Behandlung der Herzinsuffizienz und die Kontrolle der Herz-insuffizienzsymptome beschr{\"a}nkt, k{\"o}nnten β1-ECII-homologe Peptide als Antik{\"o}rper-F{\"a}nger bei Antik{\"o}rper-positiven Patienten nun einen kausalen Therapieansatz darstellen. In diesem Zusammenhang wurden ein aus 25 Aminos{\"a}uren bestehendes zyklisches Peptid, eine aus 18 Aminos{\"a}uren bestehende Zyklopeptid-Mutante und ihre jeweiligen linearen {\"A}quivalente im Rattenmodell auf Antik{\"o}rper-neutralisierende Effekte und potentielle therapeutische Wirksamkeit getestet. Das Rattenmodell ist hierf{\"u}r besonders geeignet, da die Aminos{\"a}uresequenz der funktionell wichtigen zweiten extrazellul{\"a}ren Dom{\"a}ne des β1-adrenergen Rezeptors (β1-ECII) bei Mensch und Ratte absolut identisch ist. Auf immunologischer Ebene konnte der Titer der krankheitsinduzierenden β1-ECII-Antik{\"o}rper bereits nach der ersten Applikation zyklischer Peptide relevant gesenkt werden und nahm im weiteren Verlauf der Behandlung kontinuierlich ab. Nach Zyklopeptidgabe kam es am Herzen zu einer Reduktion des linksventrikul{\"a}ren Durchmessers und zu einer fast vollst{\"a}ndigen Normalisierung der anatomischen Proportionen. Auf die Morphologie der Myozyten selbst und auch den Kollagengehalt des Gewebes hatte die Zyklopeptidtherapie keinen wesentlichen Einfluss. Die funktionellen Eigenschaften des Herzens ließen sich durch die Neutralisation stimulatorischer β1-ECII-Antik{\"o}rper mittels intraven{\"o}ser Zyklopeptidapplikation deutlich verbessern: Die Verk{\"u}rzungsfraktion des linken Ventrikels und der Herzindex als Parameter f{\"u}r die kardiale Leistungsf{\"a}higkeit konnten durch die Behandlung wieder weitgehend normalisiert werden. Diese im Tiermodell erzielten Ergebnisse lassen einen therapeutischen Effekt der Zyklopeptide vermuten. Der Ansatz einer spezifisch gegen Antik{\"o}rper gerichteten Therapie zur Behandlung von Patienten mit β1-Antik{\"o}rper-positiver Herzinsuffizienz erscheint daher vielversprechend.},
  subject      = {Dilatative Kardiomyopathie},
  language  = {de}
}
@article{Jung‐KoenigFuellenbachMurphyetal.2020,
  author    = {Jung-K{\"o}nig, Mona and F{\"u}llenbach, Christoph and Murphy, Michael F. and Manzini, Paola and Laspina, Stefan and Pendry, Kate and M{\"u}hling, J{\"o}rg and Wikman, Agneta and Humbrecht, Catherine and Rigal, Jean-Christophe and Lasocki, Sigismond and Foll{\´e}a, Gilles and Seifried, Erhard and M{\"u}ller, Markus M. and Geisen, Christof and Aranko, Kari and Zacharowski, Kai and Meybohm, Patrick},
  title     = {Programmes for the management of preoperative anaemia: audit in ten European hospitals within the PaBloE (Patient Blood Management in Europe) working group},
  series = {Vox Sanguinis},
  volume    = {115},
  journal   = {Vox Sanguinis},
  number    = {3},
  doi       = {10.1111/vox.12872},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-214049},
  pages     = {182 -- 191},
  year      = {2020},
  abstract  = {Background and objectives Preoperative anaemia is an independent risk factor for a higher morbidity and mortality, a longer hospitalization and increased perioperative transfusion rates. Managing preoperative anaemia is the first of three pillars of Patient Blood Management (PBM), a multidisciplinary concept to improve patient safety. While various studies provide medical information on (successful) anaemia treatment pathways, knowledge of organizational details of diagnosis and management of preoperative anaemia across Europe is scarce. Materials and methods To gain information on various aspects of preoperative anaemia management including organization, financing, diagnostics and treatment, we conducted a survey (74 questions) in ten hospitals from seven European nations within the PaBloE (Patient Blood Management in Europe) working group covering the year 2016. Results Organization and activity in the field of preoperative anaemia management were heterogeneous in the participating hospitals. Almost all hospitals had pathways for managing preoperative anaemia in place, however, only two nations had national guidelines. In six of the ten participating hospitals, preoperative anaemia management was organized by anaesthetists. Diagnostics and treatment focused on iron deficiency anaemia which, in most hospitals, was corrected with intravenous iron. Conclusion Implementation and approaches of preoperative anaemia management vary across Europe with a primary focus on treating iron deficiency anaemia. Findings of this survey motivated the hospitals involved to critically evaluate their practice and may also help other hospitals interested in PBM to develop action plans for diagnosis and management of preoperative anaemia.},
  language  = {en}
}
@article{SchmittMeybohmNeefetal.2022,
  author    = {Schmitt, Elke and Meybohm, Patrick and Neef, Vanessa and Baumgarten, Peter and Bayer, Alexandra and Choorapoikayil, Suma and Friederich, Patrick and Friedrich, Jens and Geisen, Christof and G{\"u}resir, Erdem and Gr{\"u}newald, Matthias and Gutjahr, Martin and Helmer, Philipp and Herrmann, Eva and M{\"u}ller, Markus and Narita, Diana and Raadts, Ansgar and Schwendner, Klaus and Seifried, Erhard and Stark, Patrick and Steinbicker, Andrea U. and Thoma, Josef and Velten, Markus and Weigt, Henry and Wiesenack, Christoph and Wittmann, Maria and Zacharowski, Kai and Piekarski, Florian},
  title     = {Preoperative anaemia and red blood cell transfusion in patients with aneurysmal subarachnoid and intracerebral haemorrhage - a multicentre subanalysis of the German PBM Network Registry},
  series = {Acta Neurochirurgica},
  volume    = {164},
  journal   = {Acta Neurochirurgica},
  organization    = {German PBM Network Collaborators},
  doi       = {10.1007/s00701-022-05144-7},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-346754},
  pages     = {985-999},
  year      = {2022},
  abstract  = {Purpose Anaemia is common in patients presenting with aneurysmal subarachnoid (aSAH) and intracerebral haemorrhage (ICH). In surgical patients, anaemia was identified as an idenpendent risk factor for postoperative mortality, prolonged hospital length of stay (LOS) and increased risk of red blood cell (RBC) transfusion. This multicentre cohort observation study describes the incidence and effects of preoperative anaemia in this critical patient collective for a 10-year period. Methods This multicentre observational study included adult in-hospital surgical patients diagnosed with aSAH or ICH of 21 German hospitals (discharged from 1 January 2010 to 30 September 2020). Descriptive, univariate and multivariate analyses were performed to investigate the incidence and association of preoperative anaemia with RBC transfusion, in-hospital mortality and postoperative complications in patients with aSAH and ICH. Results A total of n = 9081 patients were analysed (aSAH n = 5008; ICH n = 4073). Preoperative anaemia was present at 28.3\% in aSAH and 40.9\% in ICH. RBC transfusion rates were 29.9\% in aSAH and 29.3\% in ICH. Multivariate analysis revealed that preoperative anaemia is associated with a higher risk for RBC transfusion (OR = 3.25 in aSAH, OR = 4.16 in ICH, p < 0.001), for in-hospital mortality (OR = 1.48 in aSAH, OR = 1.53 in ICH, p < 0.001) and for several postoperative complications. Conclusions Preoperative anaemia is associated with increased RBC transfusion rates, in-hospital mortality and postoperative complications in patients with aSAH and ICH.},
  language  = {en}
}
@article{FischerThiesAwadetal.2022,
  author    = {Fischer, Dania and Thies, Fabian and Awad, Omar and Brat, Camilla and Meybohm, Patrick and Baer, Patrick C. and M{\"u}ller, Markus M. and Urbschat, Anja and Maier, Thorsten J. and Zacharowski, Kai and Roos, Jessica},
  title     = {Red blood cell-derived microparticles exert no cancer promoting effects on colorectal cancer cells in vitro},
  series = {International Journal of Molecular Sciences},
  volume    = {23},
  journal   = {International Journal of Molecular Sciences},
  number    = {16},
  issn      = {1422-0067},
  doi       = {10.3390/ijms23169323},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-286018},
  year      = {2022},
  abstract  = {The biomedical consequences of allogeneic blood transfusions and the possible pathomechanisms of transfusion-related morbidity and mortality are still not entirely understood. In retrospective studies, allogeneic transfusion was associated with increased rates of cancer recurrence, metastasis and death in patients with colorectal cancer. However, correlation does not imply causation. The purpose of this study was to elucidate this empirical observation further in order to address insecurity among patients and clinicians. We focused on the in vitro effect of microparticles derived from red blood cell units (RMPs). We incubated different colon carcinoma cells with RMPs and analyzed their effects on growth, invasion, migration and tumor marker expression. Furthermore, effects on Wnt, Akt and ERK signaling were explored. Our results show RMPs do not seem to affect functional and phenotypic characteristics of different colon carcinoma cells and did not induce or inhibit Wnt, Akt or ERK signaling, albeit in cell culture models lacking tumor microenvironment. Allogeneic blood transfusions are associated with poor prognosis, but RMPs do not seem to convey tumor-enhancing effects. Most likely, the circumstances that necessitate the transfusion, such as preoperative anemia, tumor stage, perioperative blood loss and extension of surgery, take center stage.},
  language  = {en}
}